ストックスクリーナーアプリを入手
72.08
1.21%
-0.88
プレマーケット:
70.80
-1.28
-1.78%
Nektar Therapeutics (NKTR) 最新ニュース
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) ... - Bluefield Daily Telegraph
Nektar Therapeutics stock hits 52-week high at 77.36 USD - Investing.com
Nektar Therapeutics stock hits 52-week high at 77.36 USD By Investing.com - Investing.com Australia
Nektar Therapeutics (NASDAQ:NKTR) Reaches New 52-Week HighHere's Why - MarketBeat
NKTR Investor Alert: Nektar Therapeutics Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards - marketscreener.com
Wedbush initiates coverage of Nektar Therapeutics (NKTR) with neutral recommendation - MSN
Wedbush Initiates Coverage on Nektar Therapeutics (NKTR) with Ne - GuruFocus
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR - GlobeNewswire Inc.
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Nektar Therapeutics Faces Investor Lawsuit Over Alleged Clinical Trial Enrollment Failures and Misleading Disclosures - TipRanks
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics - GlobeNewswire
Nektar Therapeutics (NASDAQ:NKTR) Coverage Initiated by Analysts at Wedbush - MarketBeat
NKTR Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in Nektar Therapeutics Securities Class Action Lawsuit — The Gross Law Firm - Morningstar
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Wedbush initiates Nektar Therapeutics stock with neutral rating By Investing.com - Investing.com Australia
Wedbush initiates Nektar Therapeutics stock with neutral rating - Investing.com
Holzer & Holzer, LLC Reminds Investors of May 5, 2026 Lead - GlobeNewswire
Wedbush Initiates Nektar Therapeutics at Neutral With $70 Price Target - marketscreener.com
Wedbush Starts Nektar Therapeutics (NKTR) at Neutral - StreetInsider
Nektar Therapeutics Faces High-Stakes AAD Data Test as Sky-High Valuation Leaves Little Room for Error - Bitget
A Look At Nektar Therapeutics (NKTR) Valuation As Rezpegaldesleukin Data Heads To Major Dermatology Meeting - simplywall.st
Robbins LLP Urges NKTR Stockholders Who Lost Money Investing in Nektar Therapeutics to Contact the Firm for Information About Leading the Class Action - PR Newswire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud - GlobeNewswire
Nektar Therapeutics stock is trending Tuesday: What's going on? - MSN
Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who - GlobeNewswire
Apogee strengthens case for longer-lasting eczema drug - BioPharma Dive
Apogee Therapeutics data show long-acting eczema drug induced relief with less frequent injections - statnews.com
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel ... - Bluefield Daily Telegraph
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
2 Healthcare Stocks to Buy Before They Get Bought Out - AOL.com
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class ActionNKTR - ACCESS Newswire
NKTR SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - marketscreener.com
Hudson Bay Capital Management LP Purchases Shares of 107,678 Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Upgraded by Wall Street Zen - MarketBeat
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit - PR Newswire
Nektar Q4 earnings & revenues trump estimates, pipeline in focus - MSN
Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - The AI Journal
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm - WFXG
Nektar presents rezpegaldesleukin data at dermatology meeting - Investing.com
NKTR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting - Finviz
Two skin and hair-loss studies from Nektar get oral AAD slots - Stock Titan
NKTR Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
Abivax & Nektar Therapeutics: Clinical-Stage Biotech Drug Development in 2026News and Statistics - IndexBox
2 Healthcare Shares to Consider Purchasing Before Potential Buyouts - Bitget
NKTR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nektar Therapeutics Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
How The Nektar Therapeutics (NKTR) Story Is Shifting Around Rezpeg And Fair Value Estimates - Yahoo Finance
B-Cell Lymphomas Clinical Trial Pipeline Appears Robust With 295+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart
ROSEN, A LEADING LAW FIRM, Encourages Nektar Therapeutics - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain OfficersNKTR - PR Newswire
NKTR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - TMX Newsfile
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein - GlobeNewswire
Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation - MSN
NKTR CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 - ChartMill
Nektar Therapeutics jumps on Q4 results - MSN
1.82%
大文字化:
|
ボリューム (24 時間):